person · Reporting owner

KLEIN JOSEPH III

Disclosed activity across 2 companies

Tapewire entity: 32405
SEC CIK: 0001206369

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IONIS PHARMACEUTICALS INCIONS · Entity 1182	Director	July 01, 2026	July 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IONIS PHARMACEUTICALS INC

Report date July 01, 2026 · Filed July 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,014	Ending reported balance After 2026-07-01 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-07-01 · Exercise / conversion · Acquired 11,518 · Balance 22,532 Row 2 · 2026-07-01 · Sale · Disposed 99 · Balance 22,433 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. Row 3 · 2026-07-01 · Sale · Disposed 11,419 · Balance 11,014 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.39 to $79.38 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.94 · Expires 2035-06-30	Direct	0	Reported balance After 2026-07-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-07-01 · Exercise / conversion · Disposed 11,518 · Balance 0
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.19 · Expires 2036-06-30	Direct	5,369	Reported balance After 2026-07-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-07-01 · Grant · Acquired 5,369 · Balance 5,369 F4: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F5: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	16,277	Reported balance After 2026-07-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-07-01 · Grant · Acquired 2,301 · Balance 16,277 F6: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F7: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026.
Common StockSEC Table I · non-derivative	Indirectby Son	200	Reported balance Holding disclosure · report date 2026-07-01 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 200 F3: The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.39 to $79.38 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

F3: The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F4: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F5: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.

F6: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AKCEA THERAPEUTICS, INC.

Report date October 12, 2020 · Filed October 13, 2020

Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.14 · Expires 2030-04-12	Direct	0	Reported balance After 2020-10-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-10-12 · Disposition to issuer · Disposed 26,400 · Balance 0 F1: This option, which provided for vesting of the shares on the 12-month anniversary of the date of grant, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.

Filing footnotes · ownership attribution and instrument terms

F1: This option, which provided for vesting of the shares on the 12-month anniversary of the date of grant, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 06, 2020 Filed Jul 6, 2020 21:32 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	667	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000098 · edgar.xml · derivative · entry 9 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666 Underlying: Common Stock · 667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 06, 2020 Filed Jul 6, 2020 21:32 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	667	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000098 · edgar.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
July 02, 2020 Filed Jul 6, 2020 21:32 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	889	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000098 · edgar.xml · derivative · entry 8 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,777 Underlying: Common Stock · 889 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 02, 2020 Filed Jul 6, 2020 21:32 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	889	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000098 · edgar.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
July 01, 2020 Filed Jul 6, 2020 21:32 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantDirector Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $60.20	$0.00	Disclosure SEC source: 0000874015-20-000098 · edgar.xml · derivative · entry 11 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-30 F6 · derivative.exercise_date: Grant of July 1, 2020 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2020. F6 · derivative.expiration_date: Grant of July 1, 2020 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2020. Read SEC document
July 01, 2020 Filed Jul 6, 2020 21:32 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Units · Derivative	5,333	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-20-000098 · edgar.xml · derivative · entry 10 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,333 Underlying: Common Stock · 5,333 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Grant of July 1, 2020 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2020. F5 · derivative.expiration_date: Grant of July 1, 2020 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2020. Read SEC document
July 01, 2020 Filed Jul 6, 2020 21:32 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	1,778	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000098 · edgar.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,332 Underlying: Common Stock · 1,778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 01, 2020 Filed Jul 6, 2020 21:32 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	666	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000098 · edgar.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 01, 2020 Filed Jul 6, 2020 21:32 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,778	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000098 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
July 01, 2020 Filed Jul 6, 2020 21:32 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	666	$0.00	$0.00	Disclosure SEC source: 0000874015-20-000098 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
April 13, 2020 Filed Apr 15, 2020 20:58 UTC	AKCEA THERAPEUTICS, INC. AKCA · Entity 145982	GrantStock Option (right to buy) · Derivative	26,400	$0.00 Strike: $16.14	$0.00	Disclosure SEC source: 0001209191-20-024496 · doc4.xml · derivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2030-04-12 F1 · derivative.exercise_date: The shares vest on the 12-month anniversary of the date of grant. Read SEC document
December 23, 2019 Filed Dec 24, 2019 00:28 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,000	$0.00 Strike: $35.53	$0.00	Disclosure SEC source: 0000874015-19-000156 · edgar.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. Read SEC document
December 23, 2019 Filed Dec 24, 2019 00:28 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	1,000	$61.87	$61,874.20	Disclosure SEC source: 0000874015-19-000156 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,683 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.30 to $62.345, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document
December 23, 2019 Filed Dec 24, 2019 00:28 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,000	$35.53	$35,530.00	Disclosure SEC source: 0000874015-19-000156 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. Read SEC document
December 16, 2019 Filed Dec 18, 2019 22:07 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,000	$0.00 Strike: $35.53	$0.00	Disclosure SEC source: 0000874015-19-000152 · edgar.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant. Read SEC document
December 16, 2019 Filed Dec 18, 2019 22:07 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	1,000	$65.45	$65,446.50	Disclosure SEC source: 0000874015-19-000152 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,683 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.78 to $66.135, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document
December 16, 2019 Filed Dec 18, 2019 22:07 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,000	$35.53	$35,530.00	Disclosure SEC source: 0000874015-19-000152 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. Read SEC document
December 09, 2019 Filed Dec 10, 2019 23:54 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,000	$0.00 Strike: $35.53	$0.00	Disclosure SEC source: 0000874015-19-000150 · edgar.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 1,000 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant. Read SEC document
December 09, 2019 Filed Dec 10, 2019 23:54 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	1,000	$63.74	$63,744.70	Disclosure SEC source: 0000874015-19-000150 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,683 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.44 to $64.90, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document
December 09, 2019 Filed Dec 10, 2019 23:54 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,000	$35.53	$35,530.00	Disclosure SEC source: 0000874015-19-000150 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. Read SEC document
December 02, 2019 Filed Dec 4, 2019 23:26 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,000	$0.00 Strike: $35.53	$0.00	Disclosure SEC source: 0000874015-19-000144 · edgar.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 1,000 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant. Read SEC document
December 02, 2019 Filed Dec 4, 2019 23:26 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	1,000	$64.08	$64,083.00	Disclosure SEC source: 0000874015-19-000144 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,683 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.795 to $64.92, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document
December 02, 2019 Filed Dec 4, 2019 23:26 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,000	$35.53	$35,530.00	Disclosure SEC source: 0000874015-19-000144 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. Read SEC document
November 25, 2019 Filed Nov 26, 2019 22:43 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	812	$62.90	$51,074.80	Disclosure SEC source: 0000874015-19-000140 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,683 F1 · kind: The sale of shares owned was made pursuant to a 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F1 · shares: The sale of shares owned was made pursuant to a 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.91 to $63.30, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document
November 20, 2019 Filed Nov 21, 2019 23:40 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	2,000	$60.00	$120,000.00	Disclosure SEC source: 0000874015-19-000136 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,495 F1 · kind: The sale of shares owned was made pursuant to a 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. F1 · shares: The sale of shares owned was made pursuant to a 10b5-1 Trading Plan adopted by the reporting person on 10/11/2019. Read SEC document
September 20, 2019 Filed Sep 23, 2019 20:35 UTC	AKCEA THERAPEUTICS, INC. AKCA · Entity 145982	GrantStock Option (right to buy) · Derivative	53,000	$0.00 Strike: $22.46	$0.00	Disclosure SEC source: 0001209191-19-050457 · doc4.xml · derivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2029-09-19 F1 · derivative.exercise_date: The shares vest over a four year period in equal annual installments beginning on September 20, 2019. Read SEC document
July 03, 2019 Filed Jul 3, 2019 22:46 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	667	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000102 · edgar.xml · derivative · entry 9 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 03, 2019 Filed Jul 3, 2019 22:46 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	667	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000102 · edgar.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
July 02, 2019 Filed Jul 3, 2019 22:46 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	889	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000102 · edgar.xml · derivative · entry 8 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Stock · 889 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 02, 2019 Filed Jul 3, 2019 22:46 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	889	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000102 · edgar.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
July 01, 2019 Filed Jul 3, 2019 22:46 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantDirector Stock Option (right to buy) · Derivative	16,000	$0.00 Strike: $64.80	$0.00	Disclosure SEC source: 0000874015-19-000102 · edgar.xml · derivative · entry 11 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-06-30 F5 · derivative.exercise_date: Grant of July 1, 2019 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 1, 2020. The option shall be fully vested and exercisable on July 1, 2023. The option is exercisable to 0 shares on July 1, 2019. F5 · derivative.expiration_date: Grant of July 1, 2019 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 1, 2020. The option shall be fully vested and exercisable on July 1, 2023. The option is exercisable to 0 shares on July 1, 2019. Read SEC document
July 01, 2019 Filed Jul 3, 2019 22:46 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Units · Derivative	7,110	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000102 · edgar.xml · derivative · entry 10 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Grant of July 1, 2019 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 1, 2020. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2023. The RSU is vested as to 0 shares on July 1, 2019. F4 · derivative.expiration_date: Grant of July 1, 2019 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 1, 2020. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2023. The RSU is vested as to 0 shares on July 1, 2019. Read SEC document
July 01, 2019 Filed Jul 3, 2019 22:46 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	667	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000102 · edgar.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666 Underlying: Common Stock · 667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 01, 2019 Filed Jul 3, 2019 22:46 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	666	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000102 · edgar.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 01, 2019 Filed Jul 3, 2019 22:46 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	667	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000102 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
July 01, 2019 Filed Jul 3, 2019 22:46 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	666	$0.00	$0.00	Disclosure SEC source: 0000874015-19-000102 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
July 03, 2018 Filed Jul 3, 2018 19:07 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	667	$0.00	$0.00	Disclosure SEC source: 0000874015-18-000075 · edgar.xml · derivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 03, 2018 Filed Jul 3, 2018 19:07 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	667	$0.00	$0.00	Disclosure SEC source: 0000874015-18-000075 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:07 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantDirector Stock Option (right to buy) · Derivative	16,000	$0.00 Strike: $42.88	$0.00	Disclosure SEC source: 0000874015-18-000075 · edgar.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-07-01 F5 · derivative.exercise_date: Grant of July 2, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 2, 2019. The option shall be fully vested and exercisable on July 2, 2022. The option is exercisable to 0 shares on July 2, 2018. F5 · derivative.expiration_date: Grant of July 2, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 2, 2019. The option shall be fully vested and exercisable on July 2, 2022. The option is exercisable to 0 shares on July 2, 2018. Read SEC document
July 02, 2018 Filed Jul 3, 2018 19:07 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Units · Derivative	3,555	$0.00	$0.00	Disclosure SEC source: 0000874015-18-000075 · edgar.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,555 Underlying: Common Stock · 3,555 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Grant of July 2, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 2, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 2, 2022. The RSU is vested as to 0 shares on July 2, 2018. F4 · derivative.expiration_date: Grant of July 2, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 2, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 2, 2022. The RSU is vested as to 0 shares on July 2, 2018. Read SEC document
July 01, 2018 Filed Jul 3, 2018 19:07 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Units · Derivative	2,000	$0.00	$0.00	Disclosure SEC source: 0000874015-18-000075 · edgar.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,999 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 01, 2018 Filed Jul 3, 2018 19:07 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0000874015-18-000075 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document
March 29, 2018 Filed Mar 30, 2018 19:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,000	$0.00 Strike: $24.42	$0.00	Disclosure SEC source: 0000874015-18-000055 · edgar.xml · derivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 29, 2018 Filed Mar 30, 2018 19:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	2,000	$46.15	$92,300.00	Disclosure SEC source: 0000874015-18-000055 · edgar.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document
March 29, 2018 Filed Mar 30, 2018 19:51 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	2,000	$24.42	$48,840.00	Disclosure SEC source: 0000874015-18-000055 · edgar.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document
March 15, 2018 Filed Mar 16, 2018 20:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	2,000	$0.00 Strike: $24.42	$0.00	Disclosure SEC source: 0000874015-18-000053 · edgar.xml · derivative · entry 8 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 15, 2018 Filed Mar 16, 2018 20:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	200	$52.11	$10,422.00	Disclosure SEC source: 0000874015-18-000053 · edgar.xml · nonDerivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.03 to $52.18, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document
March 15, 2018 Filed Mar 16, 2018 20:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	200	$24.42	$4,884.00	Disclosure SEC source: 0000874015-18-000053 · edgar.xml · nonDerivative · entry 5 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document
March 15, 2018 Filed Mar 16, 2018 20:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	900	$51.59	$46,431.00	Disclosure SEC source: 0000874015-18-000053 · edgar.xml · nonDerivative · entry 4 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,939 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.85, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document
March 15, 2018 Filed Mar 16, 2018 20:19 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	900	$24.42	$21,978.00	Disclosure SEC source: 0000874015-18-000053 · edgar.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.